From the 2022 AAEP Annual Convention: Anti-Inflammatories, Cataracts, and Endocrine Disease - How to Interpret the Phosphorylated Neurofilament Heavy Biomarker Test.
Dr. Peter Morressey chats with Dr. Carrie Finno, DVM, PhD, DACVIM (LAIM) regarding her study involving a definitive diagnosis of neurological disease in the equine
patient. Until recently, the only way to definitively diagnose eNAD/EDM was through postmortem histologic evaluation of the brainstem and spinal cord. A biomarker test for pNfH represents the first diagnostic antemortem testing available for eNAD/EDM.